Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | AHCY | P23526 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.36 |
| ▸ | PDE8B | O95263 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11990571 | 1.00 | KDM1A (0.45) | KDM1AAHCYATMOPRD1TP53 | |
| SCHEMBL11969463 | 0.86 | KDM1A (0.46) | KDM1AAHCYATMOPRD1MEN1 | |
| SCHEMBL11990569 | 0.84 | OPRD1 (0.47) | KDM1AAHCYATMOPRD1MEN1 | |
| SCHEMBL11969416 | 0.83 | KDM1A (0.44) | KDM1AAHCYATMOPRD1MEN1 | |
| SCHEMBL11990468 | 0.80 | CHRM1 (0.44) | TP53 | |
| SCHEMBL20012621 | 0.80 | CHRM1 (0.44) | TP53 | |
| SCHEMBL11990470 | 0.77 | LMNA (0.34) | TP53LMNADRD2 | |
| SCHEMBL17167149 | 0.77 | LMNA (0.34) | TP53LMNADRD2 | |
| SCHEMBL11969924 | 0.77 | KDM1A (0.55) | KDM1AAHCYATMOPRD1MEN1 | |
| SCHEMBL11969272 | 0.74 | OPRD1 (0.52) | KDM1AAHCYATMOPRD1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | ASANA BIOSCIENCES, LLC (US) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290182-A1 | USE OF AMINOINDANE COMPOUNDS IN TREATING OVERACTIVE BLADDER AND INTERSTITIAL CYSTITIS | IDO1, IDO2, SLC1A2 | KDM1A 2847/4885AHCY 320/4885ATM 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.